North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity

PrintEmail
Nov 2020 - 111 Pages - From $2,700
(Excel Data Sheet: $1,500)
Description

The report cover may be different from the image shown.

  • The product will be delivered as a PDF file by Email within 48 business hours upon receiving an order. 
  • To learn more about the report, please Download Free Sample Pages and Download Excel Datasheet Sample. The report will be updated before delivery, so that the most recent historic year is the base year and forecast covers 5-10 years over the base year.
  • PleaseContact Us for any question, custom research, and current discount. It is possible now to buy a part of the report such as chapters, sections, data tables or figures.
Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

North America preventive vaccines market is expected to grow by 9.98% annually in the forecast period and reach $30.01 billion by 2026 driven by increasing healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 26 tables and 48 figures, this 111-page report “North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.

Based on Vaccine Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines

Based on Disease, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases

Based on Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes

Based on Patient, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
Pediatric Vaccines
• Pneumococcal
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Hepatitis
• Poliovirus
• Haemophilus Influenzae B (HIB)
• Other Diseases
Adult Vaccines
• Influenza
• Cervical Cancer
• Hepatitis
• Zoster
• Other Diseases

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of Market Research Methodology 10
1.2.2 Market Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of North America Market by Vaccine Type 40
3.1 Market Overview by Vaccine Type 40
3.2 Live/Attenuated Vaccines 42
3.3 Inactivated Vaccines 43
3.4 Subunit Vaccines 44
3.5 Toxoid Vaccines 45
3.6 Conjugate Vaccines 46
3.7 Recombinant Vector Vaccines 47
3.8 Other Vaccines 48
4 Segmentation of North America Market by Disease 49
4.1 Market Overview by Disease 49
4.2 Vaccines for Pneumococcal Disease 51
4.3 Vaccines for Poliovirus 52
4.4 Vaccines for Hepatitis 53
4.5 Vaccines for Influenza 54
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 55
4.7 Vaccines for Varicella 56
4.8 Vaccines for Human Papilloma Virus 57
4.9 Vaccines for COVID-19 58
4.10 Vaccines for Other Diseases 59
5 Segmentation of North America Market by Administration 60
5.1 Market Overview by Administration 60
5.2 Intramuscular Route 62
5.3 Subcutaneous Route 63
5.4 Oral Route 64
5.5 Intravenous Injection 65
5.6 Other Administration Routes 66
6 Segmentation of North America Market by Patient 67
6.1 Market Overview by Patient 67
6.2 Pediatric Vaccines 69
6.3 Adult Vaccines 71
7 North America Market 2019-2026 by Country 73
7.1 Overview of North America Market 73
7.2 U.S. 76
7.3 Canada 81
7.4 Mexico 84
8 Competitive Landscape 87
8.1 Overview of Key Vendors 87
8.2 New Product Launch, Partnership, Investment, and M&A 90
8.3 Company Profiles 91
AstraZeneca plc 91
Bavarian Nordic A/S 93
China National Biotec Group Company Ltd. 94
CSL Ltd. 95
Daiichi Sankyo Co. Ltd 96
Emergent BioSolutions Inc. 97
GlaxoSmithKline PLC 98
Johnson & Johnson 99
Merck & Co. 100
Novavax, Inc. 101
Pfizer Inc. 102
Sanofi SA 103
Takeda Pharmaceutical Co. Ltd 104
9 Investing in North America Market: Risk Assessment and Management 105
9.1 Risk Evaluation of North America Market 105
9.2 Critical Success Factors (CSFs) 108
Related Reports and Products 111

List of Tables:

Table 1. Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2019-2026 17
Table 2. Growth Rate of World Real GDP, 2017-2021 22
Table 3. Main Product Trends and Market Opportunities in North America Preventive Vaccines Market 32
Table 4. North America Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 40
Table 5. North America Preventive Vaccines Market by Disease, 2016-2026, $ mn 49
Table 6. North America Preventive Vaccines Market by Administration, 2016-2026, $ mn 60
Table 7. North America Preventive Vaccines Market by Patient, 2016-2026, $ mn 67
Table 8. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 70
Table 9. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 72
Table 10. North America Preventive Vaccines Market by Country, 2016-2026, $ mn 74
Table 11. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78
Table 12. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn 78
Table 13. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn 79
Table 14. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 82
Table 15. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn 82
Table 16. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn 83
Table 17. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 85
Table 18. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 85
Table 19. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 86
Table 20. AstraZeneca plc: Company Snapshot 91
Table 21. AstraZeneca plc: Business Segmentation 91
Table 22. AstraZeneca plc: Product Portfolio 92
Table 23. AstraZeneca plc: Revenue, 2016-2018, $ mn 92
Table 24. AstraZeneca plc: Recent Developments 92
Table 25. Risk Evaluation for Investing in North America Market, 2019-2026 106
Table 26. Critical Success Factors and Key Takeaways 109

 

 

List of Figures:

Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 16
Figure 5. North America Preventive Vaccines Market, 2019-2026, $ mn 19
Figure 6. Development Stages of Preventive Vaccines 20
Figure 7. Impact of COVID-19 on Business 24
Figure 8. Primary Drivers and Impact Factors of North America Preventive Vaccines Market 26
Figure 9. Primary Restraints and Impact Factors of North America Preventive Vaccines Market 29
Figure 10. Investment Opportunity Analysis 33
Figure 11. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market 36
Figure 12. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2019-2026, % of Revenue 41
Figure 13. Contribution to North America 2020-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 41
Figure 14. North America Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 42
Figure 15. North America Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 43
Figure 16. North America Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 44
Figure 17. North America Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 45
Figure 18. North America Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 46
Figure 19. North America Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 47
Figure 20. North America Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 48
Figure 21. Breakdown of North America Preventive Vaccines Market by Disease, 2019-2026, % of Revenue 50
Figure 22. Contribution to North America 2020-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 50
Figure 23. North America Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 51
Figure 24. North America Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 52
Figure 25. North America Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 53
Figure 26. North America Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 54
Figure 27. North America Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 55
Figure 28. North America Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 56
Figure 29. North America Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 57
Figure 30. North America Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 58
Figure 31. North America Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 59
Figure 32. Breakdown of North America Preventive Vaccines Market by Administration, 2019-2026, % of Revenue 61
Figure 33. Contribution to North America 2020-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 61
Figure 34. North America Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 62
Figure 35. North America Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 63
Figure 36. North America Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 64
Figure 37. North America Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 65
Figure 38. North America Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 66
Figure 39. Breakdown of North America Preventive Vaccines Market by Patient, 2019-2026, % of Revenue 67
Figure 40. Contribution to North America 2020-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 68
Figure 41. North America Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 69
Figure 42. North America Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 71
Figure 43. Breakdown of North America Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 74
Figure 44. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 75
Figure 45. U.S. Preventive Vaccines Market, 2016-2026, $ mn 77
Figure 46. Canada Preventive Vaccines Market, 2016-2026, $ mn 81
Figure 47. Preventive Vaccines Market in Mexico, 2016-2026, $ mn 84
Figure 48. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period 87

 

Reviews

There are yet no reviews for this product.